Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4434 Treatment approaches for gastroenteropancreatic neuroendocrine neoplasms: A twelve-year experience at a single centre in Colombia

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) have multiple treatment options, but their availability varies by cost.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, treatment, Lutetium-177, surgery,

#4419 Real-world outcomes in patients with gastroenteropancreatic neuroendocrine neoplasms at a cancer centre in a middle-income country

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare tumours that are increasing in prevalence. However, the epidemiology of GEP-NENs in Latin America is not well understood.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, middle-income countries, epidemiology,

#4125 Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial

Introduction: Evidence for immunotherapy (IT) in patients (pts) with MTC is limited and has shown modest activity.

Conference:

Presenting Author:

Authors: García-Álvarez A, Molina-Cerrillo J, Castelo B, Plana M, Iglesias L,

Keywords: Medullary thyroid carcinoma, Immunotherapy, durvalumab, tremelimumab, anti PD-L1, anti CTLA-4,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#3513 Comprehensive molecular analysis of prognostic groups in Neuroendocrine Neoplasms (NENs) identifies key genes and potential regulatory mechanisms

Introduction: MiRNAs are key regulators of multiple molecular processes, including tumorigenesis and cancer progression. However, very few studies have assessed their role in NENs. In a previous study, we identified a miRNA signature that defined 3 prognostic groups in 86 patients with lung and gastroenteropancreatic (GEP) NENs. Here, we explore up- and downstream mechanisms underlying this miRNA signature.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Espinosa-Olarte P, Carretero C, Molina-Pinelo S, Robles C,

Keywords: miRNAs, Signature, omics, Molecular, Neuroendocrine Neoplasia, Lung, Gastroenteropancreatic,